Table 2.
Outcomes Data from the IFM 2009–02 of Pomalidomide with Low-dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
| Outcome Measure, n (%) | Pomalidomide 21/28 Days (n = 43) | Pomalidomide 28/28 Days (n = 41) | Total Population (N = 84) |
|---|---|---|---|
|
| |||
| Overall response rate (at least partial response) | 15 (35%) | 14 (34%) | 29 (35%) |
| Complete response rate | 1 (2%) | 2 (5%) | 3 (4%) |
| Very good partial response rate | 1 (2%) | 1 (2%) | 2 (2%) |
| Partial response rate | 13 (30%) | 11 (27%) | 24 (27%) |
| Stable disease | 19 (44%) | 21 (51%) | 40 (48%) |
| Progressive disease | 5 (12%) | 3 (7%) | 8 (10%) |
| Not evaluable | 4 (9%) | 3 (7%) | 7 (8%) |
|
| |||
| Median time to first response (months) | 2.7 | 1.1 | 1.8 |
| Median response duration (months) | 6.4 | 8.3 | 7.3 |
| One-year relapse-free survival (%) | 42% | 47% | 44% |
| Median time to progression (months) | 5.5 | 4.6 | 5.4 |
| Median progression-free survival (months) | 5.4 | 4.4 | 4.6 |
| Median overall survival (months) | 14.9 | 14.8 | 14.9 |
*
Data are from reference (93).